ArticleOncology letters2026
TBX20 regulates epithelial-mesenchymal transition, maintains tumor stemness and immune factor expression, and promotes immune escape in lung cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-box transcription factor 20 (TBX20) serves a crucial regulatory role in the process of tumor occurrence. In lung cancer, the upregulation of TBX20 expression is positively associated with a poor prognosis; however, the specific underlying mechanism remains unclear. Therefore, in the present study, the expression of TBX20 in normal lung epithelial BEAS-2B and cancer cells A549 was detected by quantitative PCR and western blot. Lung cancer cell lines with overexpression and interference of TBX20 were constructed. Cell proliferation was detected by Cell Counting Kit-8, cell migration and invasion were detected by Transwell, and cell spheroid formation was assessed. The expression of EMT markers (E-cadherin, N-cadherin, vimentin), stemness markers (CD44, Sox2, Nanog), and immune factors (PD-L1, IL-6, CCL2) was detected by qPCR and WB. A subcutaneous lung cancer model in nude mice was established. After 4 weeks, the tumor volume was observed. The expression of E-cadherin, N-cadherin, vimentin, CD44, and PD-L1 in tumor tissues was detected by IHC. The infiltration of immune cells (CD8+T, CD4+T, M1/M2 macrophages) was detected by flow cytometry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.